美股市場個股詳情

DYN 戴納基

添加自選

26.250
+0.170+0.65%

收盤價 05/06 16:00 (美東)

25.750
-0.500-1.90%

盤後 17:07 (美東)

22.94億總市值-6595市盈率TTM

戴納基股票討論區

登錄發表評論

Moomoo AI

03/25 19:38

John Cox's appointment, with his vast biotech industry and rare disease commercialization experience, is viewed positively for Dyne Therapeutics. His leadership is anticipated to enhance the company's clinical programs and pipeline, and build more capabilities as Dyne continues to create stakeholder value.

Press Release: Dyne Therapeutics Announces CEO Transition

SlowndEasyTrades

03/24 07:07

$戴納基(DYN.US)$ 🐂37.79~55.89 upswing might be risk free 🟢 zone

Moomoo AI

03/15 19:12

Recent insider share sale at current price raises slight concern. Lack of insider buying and low level of insider ownership over the past year do not inspire excitement about the stock.

Chief Operating Officer Of Dyne Therapeutics Sold 71% Of Their Shares

Moomoo AI

01/27 20:53

The lack of recent insider transactions and low insider ownership at Dyne Therapeutics doesn't inspire confidence. Insider sales at prices above current levels could suggest contentment with lower valuations, potentially a weak sign for future stock performance.

More Money In The Bank For Dyne Therapeutics Insiders Who Divested US$751k

Meltyy

01/12 23:27

Biotech Stock News 01/12 @ Open 🛎️📰
$戴納基(DYN.US)$ 4% Closing of public offering
$傑龍(GERN.US)$ 4% Participate @ B. Riley Sec. Conf. '24
$ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS(ZEAL.US)$ 2% Capital increase
$標記臨床研究(XOMA.US)$ 1% Arimoclomol NDA filing accepted
$Cellectar BioSciences(CLRB.US)$ 1% Topline results @ conf. call
$CytomX(CTMX.US)$ 0% Present @ B. Riley Sec. Conf. '24

Trytosaveabit

01/12 05:06

Update

$戴納基(DYN.US)$ Press Release: Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dow Jones· just